Randall Nelson - CardieX Independent Non-Executive Director

Director

Mr. Randall King Nelson was appointed as Independent NonExecutive Director of the Company., effective 13 November 2015. He has more than 30 years experience in the medical devices industry. He is currently President and CEO of Uptake Medical Corporationrationration, a company focused on treatments for emphysema and lung cancer. Previously, he served as president and CEO of Kerberos Proximal Solutions, which was acquired by FoxHollow Technologies and as president and CEO of VenPro, a heart valve business acquired by Medtronic. Prior to that, he spent 19 years with Baxter International and American Hospital Supply Corporation in roles of increasing responsibility that included division president for Dade Diagnostics, Bentley Labs, and Baxters Perfusion Services. Mr Nelson also served as chairman of Digirad Corporation from 2003 to 2012 since 2015.
Tenure 9 years
Phone61 2 9874 8761
Webhttp://cardiex.com

CardieX Management Efficiency

The company has return on total asset (ROA) of (16.43) % which means that it has lost $16.43 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (48.97) %, meaning that it generated substantial loss on money invested by shareholders. CardieX's management efficiency ratios could be used to measure how well CardieX manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 1.7 M in total debt with debt to equity ratio (D/E) of 0.24, which may suggest the company is not taking enough advantage from borrowing. CardieX Limited has a current ratio of 1.67, which is within standard range for the sector. Debt can assist CardieX until it has trouble settling it off, either with new capital or with free cash flow. So, CardieX's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CardieX Limited sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CardieX to invest in growth at high rates of return. When we think about CardieX's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Maria AramburuzabalaAnheuser Busch Inbev
57
Barbara SchererNETGEAR
62
Grady SummersNETGEAR
39
Elio ScetiAnheuser Busch Inbev
55
Michele BurnsAnheuser Busch Inbev
63
Joseph KeithleyAxcelis Technologies
69
Lauralee MartinKaiser Aluminum
67
Emily LiggettKaiser Aluminum
62
Gregoire SpoelberchAnheuser Busch Inbev
55
Thomas DennisAxcelis Technologies
64
Olivier GoudetAnheuser Busch Inbev
54
William GiffordAnheuser Busch Inbev
51
Christopher GenualdiNETGEAR
N/A
Kenneth ChenaultProcter Gamble
66
John KurtzweilAxcelis Technologies
61
Gregory RossmannNETGEAR
56
Jocelyn CarterMillerNETGEAR
59
Ernesto ZedilloProcter Gamble
62
Bradley MaiorinoNETGEAR
47
Julie ShimerNETGEAR
65
Carlos SicupiraAnheuser Busch Inbev
69
CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. CardieX Limited was founded in 1994 and is headquartered in Sydney, Australia. Cardiex is traded on OTC Exchange in the United States. CardieX Limited [AMDHF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

CardieX Limited Leadership Team

Elected by the shareholders, the CardieX's board of directors comprises two types of representatives: CardieX inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CardieX. The board's role is to monitor CardieX's management team and ensure that shareholders' interests are well served. CardieX's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CardieX's outside directors are responsible for providing unbiased perspectives on the board's policies.
Rhonda Welch, Vice President of Global Marketing
David Brookes, Independent Non-Executive Director
Mark Harding, VP of Global Marketing and International Sales - Atcor Medical Pty Ltd
Niall Cairns, Non-Executive Director
Chris Dax, Vice President - Operations
Peter Jenkins, Independent Non-Executive Director
Craig Cooper, CEO, Executive Director
Duncan Ross, CEO, Managing Director, Executive Director
Randall Nelson, Independent Non-Executive Director
Douglas Kurschinski, Sr. VP of Atcor Medical Inc and General Manager of Atcor Medical Inc
Michael ORourke, Non-Executive Director
Donal ODwyer, Independent Non-Executive Chairman of the Board
Peter Manley, CFO, Company Secretary

CardieX Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is CardieX a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with CardieX

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CardieX position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CardieX will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
Note that the CardieX Limited information on this page should be used as a complementary analysis to other CardieX's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Consideration for investing in CardieX OTC Stock

If you are still planning to invest in CardieX Limited check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the CardieX's history and understand the potential risks before investing.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stocks Directory
Find actively traded stocks across global markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios